A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment
A study for patients with nontuberculous mycobacterial (NTM) lung disease using study drug Liposomal Amikacin for Inhalation (LAI)
Sponsor: Insmed
Enrolling: Male and Female Patients
IRB Number: AAAQ7428
U.S. Govt. ID: NCT02344004
Contact: Angela DiMango: 212-305-5730 / amd2@cumc.columbia.edu
Additional Study Information: Our clinic is seeking patients with nontuberculous mycobacterial, or NTM, lung disease caused by Mycobacterium avium Complex (MAC), ages 18 years and older, for possible participation in a clinical trial. The CONVERT Study is evaluating the safety and effectiveness of an inhaled investigational drug called Liposomal Amikacin for Inhalation, or LAI
This study is closed
Investigator
Angela DiMango, MD
Do You Qualify?
Have you been diagnosed with NTM? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Angela DiMango
amd2@cumc.columbia.edu
212-305-5730
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE